Dragana Milojkovic
Overview
Explore the profile of Dragana Milojkovic including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
113
Citations
3410
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Innes A, Hayden C, Orovboni V, Claudiani S, Fernando F, Khan A, et al.
Leukemia
. 2024 Sep;
38(11):2443-2455.
PMID: 39300220
Asciminib is a potent and selective inhibitor of BCR::ABL1, with potential to avoid toxicity resulting from off-target kinase inhibition. Forty-nine patients treated with asciminib under a managed access program in...
2.
Fernando F, Andres M, Claudiani S, Kermani N, Ceccarelli G, Innes A, et al.
Cardiooncology
. 2024 Jul;
10(1):42.
PMID: 39010172
Background: The therapeutic landscape of chronic myeloid leukaemia (CML) has been transformed by tyrosine kinase inhibitors (TKI). Nilotinib, showed higher rates of major molecular response than imatinib, however associated with...
3.
Nesr G, Claudiani S, Milojkovic D, Innes A, Fernando F, Caballes I, et al.
Leuk Lymphoma
. 2024 Apr;
65(8):1161-1166.
PMID: 38652865
Advancements in the management of patients with chronic myeloid leukemia (CML) allowed them to achieve survival comparable with their healthy counterparts. Consequently, their care has widened with growing focus on...
4.
Claudiani S, Chee L, Fernando F, Brown L, Achandira U, Khan A, et al.
Am J Hematol
. 2024 Mar;
99(6):1172-1174.
PMID: 38436141
Probability of treatment-free remission (TFR) in CML patients with additional chromosomal abnormalities (ACA) in the Philadelphia-positive clone or variant Philadelphia translocations (ACA/Var-Ph group, blue panel), in those with no cytogenetic...
5.
Claudiani S, Chughtai F, Khan A, Hayden C, Fernando F, Khorashad J, et al.
Leukemia
. 2024 Feb;
38(4):796-802.
PMID: 38424138
Second-generation tyrosine kinase inhibitors (2GTKI) are more effective in inducing rapid molecular responses than imatinib when used first-line in patients with chronic myeloid leukemia in chronic phase (CML-CP). However, failure...
6.
Fang Z, Corbizi Fattori G, McKerrell T, Boucher R, Jackson A, Fletcher R, et al.
Nat Commun
. 2023 Nov;
14(1):7725.
PMID: 38001082
Current therapies for myeloproliferative neoplasms (MPNs) improve symptoms but have limited effect on tumor size. In preclinical studies, tamoxifen restored normal apoptosis in mutated hematopoietic stem/progenitor cells (HSPCs). TAMARIN Phase-II,...
7.
May P, Reid A, Robinson M, Khorashad J, Milojkovic D, Claudiani S, et al.
BMC Med Genomics
. 2023 Jul;
16(1):172.
PMID: 37496024
Background: Chronic myeloid leukaemia (CML) is one of the most well characterised human malignancies. Most patients have a cytogenetically visible translocation between chromosomes 9 and 22 which generates the pathognomonic...
8.
Milojkovic D, Lyon A, Mehta P, Dimitriadou E, Choudhuri S, Manisty C, et al.
Eur J Haematol
. 2023 May;
111(2):201-210.
PMID: 37186398
Introduction: Tyrosine kinase inhibitors (TKIs) have become the mainstay of treatment for chronic myeloid leukaemia (CML), but cardiovascular (CV) risk and exacerbation of underlying risk factors associated with TKIs have...
9.
Fernando F, Innes A, Claudiani S, Pryce A, Hayden C, Byrne J, et al.
Bone Marrow Transplant
. 2023 Apr;
58(7):826-828.
PMID: 37015970
No abstract available.
10.
Milojkovic D, Reynolds C, Munoz Sandoval D, Pieper F, Liu S, Pade C, et al.
Leukemia
. 2022 Dec;
37(1):244-247.
PMID: 36528708
No abstract available.